Table of Content

Open Access iconOpen Access

REVIEW

Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk

Nicholas A. Boncher1, Gino J. Vricella1, Michael Smith2, Matthew Passalacqua3, Vikas Gulani2, Lee E. Ponsky1

1 Urology Institute, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
2 Department of Internal Medicine, Division of Nephrology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
3 Department of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
Address correspondence to Dr. Lee E. Ponsky, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, Ohio 44106-5046 USA

Canadian Journal of Urology 2012, 19(1), 6074-6080.

Abstract

Introduction: Contrast-enhanced cross-sectional imaging is essential to the urologist's practice. Traditionally, patients with impaired renal function could not be imaged with a computed tomography (CT) scan with contrast due to the risk of contrast-induced nephropathy (CIN). These patients could alternatively be imaged by magnetic resonance imaging (MRI) with gadolinium. However, the recent identification of the association between nephrogenic systemic fibrosis (NSF) and gadolinium administration has created significant challenges for urologists and radiologists when faced with the need for evaluation with contrast-enhanced cross-sectional imaging. In this review, we summarize the most comprehensive articles discussing both NSF and CIN and present a straightforward, evidence-based algorithm to determine the appropriate approach to cross-sectional imaging for all patients, as well as future directions regarding cross-sectional imaging.
Materials and methods: A MEDLINE literature search for review articles from 1966 to August 2009 was performed. Selected additional articles for specific topics were also reviewed. This search yielded a total of 25 articles for NSF and 28 for CIN that were reviewed.
Results: The pathophysiology and risk factors of NSF and CIN are discussed, as well as potential interventions to decrease either morbidity or incidence. A multidisciplinary (urologist, nephrologist, radiologist) evidence-based algorithm is introduced for managing patients in need of cross-sectional imaging.
Conclusions: The associated risks of contrast-enhanced, cross-sectional imaging has created significant challenges for urologic evaluation. We propose an evidence-based approach to guide patient therapy, which can minimize patient risk and physician anxiety, while simplifying the decision-making process.

Keywords

magnetic resonance imaging, end-stage renal disease, contrast-induced nephropathy, nephrogenic systemic fibrosis, computed tomography

Cite This Article

APA Style
Boncher, N.A., Vricella, G.J., Smith, M., Passalacqua, M., Gulani, V. et al. (2012). Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. Canadian Journal of Urology, 19(1), 6074–6080.
Vancouver Style
Boncher NA, Vricella GJ, Smith M, Passalacqua M, Gulani V, Ponsky LE. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. Can J Urology. 2012;19(1):6074–6080.
IEEE Style
N.A. Boncher, G.J. Vricella, M. Smith, M. Passalacqua, V. Gulani, and L.E. Ponsky, “Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk,” Can. J. Urology, vol. 19, no. 1, pp. 6074–6080, 2012.



cc Copyright © 2012 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 138

    View

  • 113

    Download

  • 0

    Like

Share Link